On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial

Jemima A Frimpong, Thomas D'Aunno, David C Perlman, Shiela M Strauss, Alissa Mallow, Diana Hernandez, Bruce R Schackman, Daniel J Feaster, Lisa R Metsch, Jemima A Frimpong, Thomas D'Aunno, David C Perlman, Shiela M Strauss, Alissa Mallow, Diana Hernandez, Bruce R Schackman, Daniel J Feaster, Lisa R Metsch

Abstract

Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25 % of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD).

Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs.

Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades.

Trial registration: ClinicalTrials.gov: NCT02355080 . (30 January 2015).

Figures

Fig. 1
Fig. 1
Flow diagram of the trial design: on-site bundled rapid HIV/HCV testing randomized controlled trial (RCT). The diagram illustrates the progression of participants through the different points of the study

References

    1. Centers for Disease Control and Prevention: HIV in the united States: At A Glance. . Accessed 12 June 2015.
    1. Centers for Disease Control and Prevention: The ABCs of hepatitis. . Accessed 21 October 2012.
    1. Armstrong GL, Wasley AM, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714. doi: 10.7326/0003-4819-144-10-200605160-00004.
    1. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res. 2010;85:303–315. doi: 10.1016/j.antiviral.2009.10.021.
    1. Thomas DL. The Challenge of Hepatitis C in the HIV-Infected Person. Annu Rev Med. 2008;59:473–485. doi: 10.1146/annurev.med.59.081906.081110.
    1. Abuse S, Administration MHS. Center for Behavioral Health Statistics and Quality. The NSDUH Report: HIV/AIDS and Substance Use. 2010.
    1. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46:1852–1858. doi: 10.1086/588297.
    1. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. 2004;99:1167–1175. doi: 10.1111/j.1360-0443.2004.00821.x.
    1. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL, Strauss S. Non-injection drug use and Hepatitis C Virus: a systematic review. Drug Alcohol Depend. 2007;89:1–12. doi: 10.1016/j.drugalcdep.2006.11.014.
    1. Centers for Disease Control and Prevention: Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2011. . Accessed 14 March 2014.
    1. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55:1652–1661. doi: 10.1002/hep.25556.
    1. Department of Health and Human Services (DHHS): Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis . . Accessed 9 June 2015. 2015.
    1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med. 2012;156:271–278. doi: 10.7326/0003-4819-156-4-201202210-00004.
    1. Centers for Disease Control and Prevention Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47(19):1–39.
    1. Centers for Disease Control and Prevention Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. 2006;55(14):1–17.
    1. Strauss SM, Astone J, Vassilev ZP, Des Jarlais DC, Hagan H. Gaps in the drug-free and methadone treatment program response to Hepatitis C. J Subst Abuse Treat. 2003;24:291–297. doi: 10.1016/S0740-5472(03)00037-0.
    1. Abraham AJ, O'Brien LA, Knudsen HK, Bride BE, Smith GR, Roman PM. Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs. J Subst Abuse Treat. 2013;44:120–125. doi: 10.1016/j.jsat.2012.03.004.
    1. Brown LS, Kritz S, Goldsmith RJ, Bini EJ, Robinson J, Alderson D, Rotrosen J. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep. 2007;122:441–451.
    1. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53:619–624.
    1. D'Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV Testing in the Nation's Opioid Treatment Programs, 2005–2011: The Role of State Regulations. Health Serv Res. 2014;49(1):230–248. doi: 10.1111/1475-6773.12094.
    1. Frimpong JA, D’Aunno T, Jiang L. Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study. Am J Public Health. 2014;104(6):75–82. doi: 10.2105/AJPH.2013.301827.
    1. Bini EJ, Kritz S, Brown LS, Robinson J, Alderson D, Rotrosen J. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis. 2011;30:98–109. doi: 10.1080/10550887.2011.554780.
    1. Frimpong JA. Missed opportunities for hepatitis C testing in opioid treatment programs. Am J Public Health. 2013;103:1028–1030. doi: 10.2105/AJPH.2012.301129.
    1. Umbricht-Schneiter A, Ginn DH, Pabst KM, Bigelow GE. Providing medical care to methadone clinic patients: referral vs on-site care. Am J Public Health. 1994;84:207–210. doi: 10.2105/AJPH.84.2.207.
    1. Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, Tross S, Kyle T, Gallup D, Kosinski AS, et al. Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers: Results of a Randomized Trial. Am J Public Health. 2012;102:1160–1167. doi: 10.2105/AJPH.2011.300460.
    1. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101:2151–2155. doi: 10.2105/AJPH.2011.300251.
    1. Franco-Paredes C, Tellez I, del Rio C. Rapid HIV testing: a review of the literature and implications for the clinician. Curr HIV/AIDS Rep. 2006;3:169–175. doi: 10.1007/s11904-006-0012-3.
    1. Grusky O, Roberts KJ, Swanson AN. Failure to return for HIV test results: a pilot study of three community testing sites. J Int Assoc Physicians AIDS Care (Chic) 2007;6:47–55. doi: 10.1177/1545109706297530.
    1. Sullivan PS, Lansky A, Drake A. Failure to return for HIV test results among persons at high risk for HIV infection: results from a multistate interview project. J Acquir Immune Defic Syndr. 2004;35:511–518. doi: 10.1097/00126334-200404150-00009.
    1. Schwartz RP, Stitzer ML, Feaster DJ, Korthuis PT, Alvanzo AAH, Winhusen TM, Donnard L, Snead N, Metsch LR. HIV rapid testing in drug treatment: comparison across treatment modalities. J Subst Abuse Treat. 2013;44:369–374. doi: 10.1016/j.jsat.2012.08.219.
    1. Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM. Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus. J Infect Dis. 2011;204:825–831. doi: 10.1093/infdis/jir422.
    1. Pilcher CD, Christopoulos KA, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. J Infect Dis. 2010;201(Suppl 1):S7–15. doi: 10.1086/650393.
    1. Branson BM. HIV Testing Updates and Challenges: When Regulatory Caution and Public Health Imperatives Collide. Curr HIV/AIDS Rep. 2015;12:117–126. doi: 10.1007/s11904-014-0251-7.
    1. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis CA Systematic Review and Meta-analysis. Ann Intern Med. 2012;157:558–566. doi: 10.7326/0003-4819-157-8-201210160-00006.
    1. Stopka TJ, Marshall C, Bluthenthal RN, Webb DS, Truax SR. HCV and HIV counseling and testing integration in California: an innovative approach to increase HIV counseling and testing rates. Public Health Rep. 2007;122(Suppl 2):68–73.
    1. Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis. 2005;41(Suppl 1):S83–88. doi: 10.1086/429502.
    1. Strauss SM, Astone JM, Des Jarlais DC, Hagan H. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. AIDS Patient Care STDS. 2005;19:78–88. doi: 10.1089/apc.2005.19.78.
    1. Ward JW, Fenton KA. CDC and progress toward integration of HIV, STD, and viral hepatitis prevention. Public Health Rep. 2007;122(Suppl 2):99–101.
    1. Centers for Disease Control and Prevention: National hepatitis C prevention strategy. . Accessed 12 January 2012.
    1. Buffington J, Jones TS. Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health. Public Health Rep. 2007;122(Suppl 2):1–5.
    1. Volkow ND, Montaner J. The Urgency Of Providing Comprehensive And Integrated Treatment For Substance Abusers With HIV. Health Aff. 2011;30:1411–1419. doi: 10.1377/hlthaff.2011.0663.
    1. Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol. 2013;29:243–249.
    1. Busch SH, Meara E, Huskamp HA, Barry CL. Characteristics of Adults with Substance Use Disorders Expected to Be Eligible for Medicaid Under the ACA. Psychiatr Serv. 2013;64:520–526. doi: 10.1176/appi.ps.201200011.
    1. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med. 2015;163(3):215–223. doi: 10.7326/M15-0406.
    1. Canary LA, Klevens RM, Holmberg SD. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs. Ann Intern Med. 2015;163(3):226–228. doi: 10.7326/M15-0320.
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50:217–226. doi: 10.1097/MLR.0b013e3182408812.
    1. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156:5–10. doi: 10.1176/ajp.156.1.5.
    1. Carroll KM, Rounsaville BJ. Bridging the gap: a hybrid model to link efficacy and effectiveness research in substance abuse treatment. Psychiatr Serv. 2003;54:333–339. doi: 10.1176/appi.ps.54.3.333.
    1. August GJ, Winters KC, Realmuto GM, Tarter R, Perry C, Hektner JM. Moving evidence-based drug abuse prevention programs from basic science to practice: "bridging the efficacy-effectiveness interface". Subst Use Misuse. 2004;39:2017–2053. doi: 10.1081/JA-200033240.
    1. Cully JA, Armento ME, Mott J, Nadorff MR, Naik AD, Stanley MA, Sorocco KH, Kunik ME, Petersen NJ, Kauth MR. Brief cognitive behavioral therapy in primary care: a hybrid type 2 patient-randomized effectiveness-implementation design. Implement Sci. 2012;7:64. doi: 10.1186/1748-5908-7-64.
    1. Wingood GM, DiClemente RJ. The ADAPT-ITT model: a novel method of adapting evidence-based HIV Interventions. J Acquir Immune Defic Syndr. 2008;47(Suppl 1):S40–46. doi: 10.1097/QAI.0b013e3181605df1.
    1. Latham TP, Sales JM, Boyce LS, Renfro TL, Wingood GM, DiClemente RJ, Rose E. Application of ADAPT-ITT: adapting an evidence-based HIV prevention intervention for incarcerated African American adolescent females. Health Promot Pract. 2010;11:53S–60S. doi: 10.1177/1524839910361433.
    1. Wingood GM, Simpson-Robinson L, Braxton ND, Raiford JL. Design of a faith-based HIV intervention: successful collaboration between a university and a church. Health Promot Pract. 2011;12:823–831. doi: 10.1177/1524839910372039.
    1. Harden RM, Gleeson FA. Assessment of clinical competence using an objective structured clinical examination (OSCE) Med Educ. 1979;13:41–54.
    1. Olive KE, Elnicki DM, Kelley MJ. A practical approach to developing cases for standardized patients. Adv Health Sci Educ Theory Pract. 1997;2:49–60. doi: 10.1023/A:1009704030279.
    1. Rogers E. Diffusion of innovations. 5. New York, NY: Free Press; 2003.
    1. Rogers EM. Diffusion of innovations. New York: The Free Press; 1995.
    1. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82:581–629. doi: 10.1111/j.0887-378X.2004.00325.x.
    1. Lehman WE, Simpson DD, Knight DK, Flynn PM. Integration of treatment innovation planning and implementation: strategic process models and organizational challenges. Psychol Addict Behav. 2011;25:252–261. doi: 10.1037/a0022682.
    1. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121:710–719.
    1. Network/Promesa A: Behavioral Health Services. . Accessed 22 June 2015.
    1. Centers for Disease Control and Prevention Revised guidelines for HIV counseling, testing, and referral. Morb Mortal Wkly Rep. 2001;50(19):1–58.
    1. Craw JA, Gardner LI, Marks G, Rapp RC, Bosshart J, Duffus WA, Rossman A, Coughlin SL, Gruber D, Safford LA, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr. 2008;47:597–606. doi: 10.1097/QAI.0b013e3181684c51.
    1. Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, Sansom SL, Siegal HA, Greenberg AE, Holmberg SD. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19:423–431. doi: 10.1097/01.aids.0000161772.51900.eb.
    1. Larios SE, Masson CL, Shopshire MS, Hettema J, Jordan AE, McKnight C, Young C, Khalili M, Seewald RM, Min A, et al. Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis. J Subst Abuse Treat. 2014;46:528–531. doi: 10.1016/j.jsat.2013.10.012.
    1. Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, Jordan AE, Pepper N, Hall J, Hengl NS, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013;103:e81–88. doi: 10.2105/AJPH.2013.301458.
    1. Johnson TL, Toliver JC, Mao L, Oramasionwu CU. Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study. BMC Infect Dis. 2014;14:217. doi: 10.1186/1471-2334-14-217.
    1. Mensch BS, Hewett PC, Gregory R, Helleringer S. Sexual Behavior and STI/HIV Status Among Adolescents in Rural Malawi: An Evaluation of the Effect of Interview Mode on Reporting. Stud Fam Plann. 2008;39:321–334. doi: 10.1111/j.1728-4465.2008.00178.x.
    1. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J Am Stat Assoc. 1995;90:106–121. doi: 10.1080/01621459.1995.10476493.
    1. Suh T, Mandell W, Latkin C, Kim J. Social network characteristics and injecting HIV-risk behaviors among street injection drug users. Drug Alcohol Depend. 1997;47:137–143. doi: 10.1016/S0376-8716(97)00082-3.
    1. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9:27–39. doi: 10.1007/s10461-005-1679-y.
    1. Costenbader EC, Astone NM, Latkin CA. The dynamics of injection drug users' personal networks and HIV risk behaviors. Addiction. 2006;101:1003–1013. doi: 10.1111/j.1360-0443.2006.01431.x.
    1. De P, Cox J, Boivin JF, Platt RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction. 2007;102:1730–1739. doi: 10.1111/j.1360-0443.2007.01936.x.
    1. Romano CM, de Carvalho-Mello IM, Jamal LF, de Melo FL, Iamarino A, Motoki M, Pinho JR, Holmes EC, de Andrade Zanotto PM, Consortium V. Social networks shape the transmission dynamics of hepatitis C virus. PLoS ONE. 2010;5:e11170. doi: 10.1371/journal.pone.0011170.
    1. Pilon R, Leonard L, Kim J, Vallee D, De Rubeis E, Jolly AM, Wylie J, Pelude L, Sandstrom P. Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs. PLoS ONE. 2011;6:e22245. doi: 10.1371/journal.pone.0022245.
    1. Yang C, Tobin K, Latkin C. Perceived serosorting of injection paraphernalia sharing networks among injection drug users in Baltimore, MD. AIDS Behav. 2011;15:16–21. doi: 10.1007/s10461-010-9713-0.
    1. Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103:e44–52. doi: 10.2105/AJPH.2012.300874.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever